Novartis to buy radiology specialist Mariana Oncology for US$1 billion
Mariana Oncology is a preclinical-stage biotechnology company focused on developing novel radioligand therapies to treat cancers
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
NOVARTIS has entered an agreement to acquire US radiopharmaceutical company Mariana Oncology for US$1 billion, boosting its portfolio of cancer treatments in development, the Swiss drug manufacturer said on Thursday (May 2).
The deal also includes US$750 million of potential further payments upon achieving certain milestones, it added.
Mariana Oncology is a preclinical-stage biotechnology company focused on developing novel radioligand therapies (RLTs) to treat cancers.
“The transaction bolsters the Novartis RLT pipeline and expands the company’s research infrastructure and clinical supply capabilities,” Novartis said in a statement.
Novartis has been cutting jobs and costs, and spun off its generic drugs business Sandoz last year, part of a focus on fewer therapeutic areas and geographic markets.
In February, it struck a deal to buy German cancer drug developer MorphoSys for US$2.89 billion. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Air India asks Tata, Singapore Airlines for funds after US$2.4 billion loss
‘Boring’ is the new black: The stars are aligning for a Singapore stock market revival
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
South-east Asian markets account for 8.8% of global capital inflows from 2021 to 2024: report
